A 3-year course of bulevirtide monotherapy may cure HDV infection in patients with cirrhosis

被引：16

作者：

Anolli, Maria Paola ^{[1
]}

Degasperi, Elisabetta ^{[1
]}

Allweiss, Lena ^{[2
,3
]}

Sangiovanni, Angelo ^{[1
]}

Maggioni, Marco ^{[4
]}

Scholtes, Caroline ^{[5
,6
,7
]}

Oberhardt, Valerie ^{[8
]}

Neumann-Haefelin, Christoph ^{[8
]}

Dandri, Maura ^{[2
,3
]}

Zoulim, Fabien ^{[5
,6
,7
]}

Lampertico, Pietro ^{[1
,9
,10
]}

机构：

[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Milan, Italy

[2] Univ Med Ctr Hamburg Eppendorf, Dept Internal Med, Hamburg, Germany

[3] German Ctr Infect Res DZIF, Hamburg Lubeck Borstel Riems Site, Hamburg, Germany

[4] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Pathol Unit, Milan, Italy

[5] Hosp Civils Lyon HCL, Hepatol Dept, Lyon, France

[6] Univ Claude Bernard Lyon 1 UCBL1, Lyon, France

[7] Ctr Rech Canc Lyon CRCL, INSERM U1052, Lyon, France

[8] Univ Freiburg, Freiburg Univ Med Ctr, Fac Med, Dept Med 2, Freiburg, Germany

[9] Univ Milan, CRC AM&A Migliavacca Ctr Liver Dis, Dept Pathophysiol & Transplantat, Milan, Italy

[10] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Via F Sforza 35, I-20122 Milan, Italy

来源：

JOURNAL OF HEPATOLOGY | 2023年 / 78卷 / 04期

关键词：

Bulevirtide; HDV; HDV RNA; HBV; compensated cirrhosis; sustained virological response; clinically significant portal hypertension; liver fibrosis; HBcrAg; PBMC; HEPATITIS-D; MULTICENTER; EFFICACY; SAFETY;

D O I：

10.1016/j.jhep.2022.12.023

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Bulevirtide recently received conditional approval from the EMA for the treatment of chronic hepatitis delta, but the ideal duration of therapy is unknown. Herein, we describe the first case of hepatitis delta cure following 3 years of bulevirtide monotherapy in a patient with compensated cirrhosis and esophageal varices. During the 72-week off-bulevirtide follow-up, virological and biochemical responses were maintained. In the off-therapy liver biopsy, intrahepatic HDV RNA and hepatitis D antigen were undetectable, <1% of hepatocytes were hepatitis B surface antigen positive and all were negative for hepatitis B core antigen. Ishak grading and staging were improved following treatment.(c) 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

引用

页码：876 / 880

页数：5

共 11 条

[1]

Cornberg M, 2020, HEPATOLOGY, V71, P1070, DOI [10.1002/hep.31030, 10.1016/j.jhep.2019.11.003]

[2] Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension [J].

Degasperi, Elisabetta ;

Anolli, Maria Paola ;

Renteria, Sara Colonia Uceda ;

Sambarino, Dana ;

Borghi, Marta ;

Perbellini, Riccardo ;

Scholtes, Caroline ;

Facchetti, Floriana ;

Loglio, Alessandro ;

Monico, Sara ;

Fraquelli, Mirella ;

Costantino, Andrea ;

Ceriotti, Ferruccio ;

Zoulim, Fabien ;

Lampertico, Pietro .

JOURNAL OF HEPATOLOGY, 2022, 77 (06) :1525-1531

[3]

Dietz C, 2022, J HEPATOL, V77, pS823

[4]

Fontaine H, 2022, J HEPATOL, V77, pS72

[5] Late HDV RNA Relapse After Peginterferon Alpha-Based Therapy of Chronic Hepatitis Delta [J].

Heidrich, Benjamin ;

Yurdaydin, Cihan ;

Kabacam, Gokhan ;

Ratsch, Boris A. ;

Zachou, Kalliopi ;

Bremer, Birgit ;

Dalekos, George N. ;

Erhardt, Andreas ;

Tabak, Fehmi ;

Yalcin, Kendal ;

Gurel, Selim ;

Zeuzem, Stefan ;

Cornberg, Markus ;

Bock, C. -Thomas ;

Manns, Michael P. ;

Wedemeyer, Heiner .

HEPATOLOGY, 2014, 60 (01) :87-97

[6] Liver-Resident Bystander CD8+ T Cells Contribute to Liver Disease Pathogenesis in Chronic Hepatitis D Virus Infection [J].

Kefalakes, Helenie ;

Horgan, Xylia J. ;

Jung, Min Kyung ;

Amanakis, Georgios ;

Kapuria, Devika ;

Bolte, Fabian J. ;

Kleiner, David E. ;

Koh, Christopher ;

Heller, Theo ;

Rehermann, Barbara .

GASTROENTEROLOGY, 2021, 161 (05) :1567-+

[7] Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis [J].

Loglio, Alessandro ;

Ferenci, Peter ;

Renteria, Sara Colonia Uceda ;

Tham, Christine Y. L. ;

Scholtes, Caroline ;

Holzmann, Heidemarie ;

van Boemmel, Florian ;

Borghi, Marta ;

Perbellini, Riccardo ;

Rimondi, Alessandro ;

Farina, Elisa ;

Trombetta, Elena ;

Manunta, Maria ;

Porretti, Laura ;

Prati, Daniele ;

Ceriotti, Ferruccio ;

Zoulim, Fabien ;

Bertoletti, Antonio ;

Lampertico, Pietro .

JOURNAL OF HEPATOLOGY, 2022, 76 (02) :464-469

[8] Hepatitis C and D, retroviruses and autoimmune manifestations [J].

Obermayer-Straub, P ;

Manns, MP .

JOURNAL OF AUTOIMMUNITY, 2001, 16 (03) :275-285

[9] Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease [J].

Urban, Stephan ;

Neumann-Haefelin, Christoph ;

Lampertico, Pietro .

GUT, 2021, 70 (09) :1782-1794

[10] Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection [J].

Wedemeyer, H. ;

Bogomolov, P. ;

Blank, A. ;

Allweiss, L. ;

Dandri-Petersen, M. ;

Bremer, B. ;

Voronkova, N. ;

Schoeneweis, K. ;

Pathil, A. ;

Burhenne, J. ;

Haag, M. ;

Schwab, M. ;

Haefeli, W. -E. ;

Wiesch, J. S. Z. ;

Alexandrov, A. ;

Urban, S. .

JOURNAL OF HEPATOLOGY, 2018, 68 :S3-S3

← 1 2 →